Clinical Trial

A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The primary purpose of this study is to evaluate the long-term safety and efficacy of verekitug (UPB-101) in participants who complete the VALIANT study (NCT06196879).
Protocol Amendment History 2 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-04-03
notable Trial sites expanded: 84 -> 102 locations 2026-04-03
Trial Details
NCT Number NCT06966479
Lead Sponsor Upstream Bio Inc.
Conditions Severe Asthma
Enrollment 396 participants
Start Date 2025-05-21
Primary Completion 2027-09 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2026-05-14